Publicly available records indicate that a class action lawsuit has been filed on behalf of investors in Teva Pharmaceutical Industries (NYSE:TEVA) in connection to alleged violations of securities laws by TEVA. Fitapelli Kurta is interested in hearing from investors who have complaints regarding investments made in Teva Pharmaceutical Industries between November 15, 2016 and August 2, 2017.
The class action complaint specifically alleges that during the period in question, TEVA might have provided false and/or misleading material information, and/or failed to disclose adverse material information to the public, chiefly: that the company’s Unites States-based generics operations suffered performance problems, causing the company to record a goodwill impairment charge in connection to its acquisition of Actavis Generics, factors that contributed to the company’s dividend being reduced by 75%. The complaint alleges that when true details came to light, investors suffered losses.
According to the company’s website, Teva Pharmaceutical Industries is a pharmaceutical company “committed to increasing access to high-quality healthcare for people across the globe, at every stage of life.” The company’s description continues: “We do this by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients… Our dedication to quality in everything we do is uncompromising, and covers every stage of the development, production and marketing of our medicines: from the supply of materials through manufacturing and approval by the strictest authorities in the world. Our state-of-the-art manufacturing facilities feature the most advanced testing equipment to guarantee the quality of our products. Equipment is tested and certified, and every manufacturing process is validated. All supplier procedures are strictly supervised to ensure that only the highest grade materials are used in our products.”